tiprankstipranks
Advertisement
Advertisement

PYXS Stock Latest News

Pyxis Oncology files to sell 39.2M shares of common stock for holders
The FlyPyxis Oncology files to sell 39.2M shares of common stock for holders
16d ago
PYXS
Buy Rating Reiterated on Pyxis Ahead of Pivotal MICVO Phase 1 Readout; $7 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on Pyxis Ahead of Pivotal MICVO Phase 1 Readout; $7 Price Target Maintained
19d ago
PYXS
Pyxis Oncology reports Q2 EPS (40c), consensus (35c)
PremiumThe Fly
Pyxis Oncology reports Q2 EPS (40c), consensus (35c)
20d ago
PYXS
Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target Maintained
23d ago
PYXS
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value
PremiumCompany Announcements
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value
23d ago
PYXS
Pyxis Oncology initiated with an Overweight at Wells Fargo
PremiumThe FlyPyxis Oncology initiated with an Overweight at Wells Fargo
1M ago
PYXS
Pyxis Oncology Raises Capital Through Private Placement Financing
Premium
Company Announcements
Pyxis Oncology Raises Capital Through Private Placement Financing
2M ago
8K
PYXS
Pyxis Oncology announces up to $114M private placement
Premium
The Fly
Pyxis Oncology announces up to $114M private placement
2M ago
PYXS
Pyxis Oncology Stockholders Approve Directors and Auditor Slate
PremiumCompany Announcements
Pyxis Oncology Stockholders Approve Directors and Auditor Slate
3M ago
8K
PYXS
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility
PremiumCompany Announcements
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility
4M ago
PYXS
Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)
PremiumThe Fly
Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)
4M ago
PYXS
PYXS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
PYXS Earnings this Week: How Will it Perform?
4M ago
PYXS
Wedbush bullish on Pyxis Oncology, initiates with an Outperform
PremiumThe FlyWedbush bullish on Pyxis Oncology, initiates with an Outperform
4M ago
PYXS
Pyxis Oncology initiated with an Outperform at Wedbush
Premium
The Fly
Pyxis Oncology initiated with an Outperform at Wedbush
4M ago
PYXS
Pyxis Oncology price target lowered to $8 from $9 at Stifel
Premium
The Fly
Pyxis Oncology price target lowered to $8 from $9 at Stifel
6M ago
PYXS
Pyxis Oncology Reports Q4 Results, Advances MICVO Program
PremiumCompany Announcements
Pyxis Oncology Reports Q4 Results, Advances MICVO Program
6M ago
8K
PYXS
PYXS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
PYXS Earnings this Week: How Will it Perform?
6M ago
PYXS
Pyxis Oncology Announces Interim CEO Amid Leadership Transition
PremiumCompany Announcements
Pyxis Oncology Announces Interim CEO Amid Leadership Transition
7M ago
8K
PYXS
Pyxis Oncology appoints board member Thomas Civik as Interim CEO
PremiumThe Fly
Pyxis Oncology appoints board member Thomas Civik as Interim CEO
7M ago
PYXS
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
PremiumMarket News3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
9M ago
PYXS
RGNX
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital
Premium
The Fly
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital
9M ago
PYXS
Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
Premium
Ratings
Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
9M ago
PYXS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >